Published in Clin Cancer Res on December 15, 2010
Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist (2013) 1.49
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. Breast Cancer Res Treat (2012) 1.32
Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control (2013) 1.13
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2014) 1.11
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol (2015) 1.09
Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res (2014) 1.03
μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology (2012) 1.03
A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput Biol (2014) 1.01
Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers. J Proteome Res (2012) 1.01
Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res (2015) 1.00
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer (2012) 1.00
DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res (2014) 0.98
Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. Cancer Epidemiol Biomarkers Prev (2015) 0.96
Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat (2012) 0.96
Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health (2011) 0.95
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat (2013) 0.93
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health (2015) 0.92
Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. Cancer Epidemiol Biomarkers Prev (2013) 0.89
Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res (2013) 0.88
Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol (2011) 0.88
Integrative physical oncology. Wiley Interdiscip Rev Syst Biol Med (2011) 0.88
Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol (2013) 0.87
High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG. J Biol Chem (2012) 0.87
A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer (2015) 0.87
Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer (2013) 0.87
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis. Oncotarget (2015) 0.87
Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients. Curr Oncol (2013) 0.86
In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. Cancer Res (2011) 0.85
Modelling breast cancer requires identification and correction of a critical cell lineage-dependent transduction bias. Nat Commun (2015) 0.85
Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat (2014) 0.84
Expression of activator protein-1 (AP-1) family members in breast cancer. BMC Cancer (2013) 0.84
Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev (2013) 0.84
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat (2014) 0.83
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One (2014) 0.83
Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev (2015) 0.82
Genetic ancestry and risk of mortality among U.S. Latinas with breast cancer. Cancer Res (2013) 0.82
Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv (2014) 0.81
Race-associated biological differences among Luminal A breast tumors. Breast Cancer Res Treat (2015) 0.81
Association between mammographic density and basal-like and luminal A breast cancer subtypes. Breast Cancer Res (2013) 0.81
Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular subclassification study. JRSM Short Rep (2013) 0.81
Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer. Springerplus (2013) 0.80
Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat (2015) 0.80
Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. J Clin Oncol (2016) 0.79
Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D. Med Oncol (2016) 0.78
Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil. BMC Womens Health (2014) 0.78
HER2 status and disparities in luminal breast cancers. Cancer Med (2016) 0.78
Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Aff (Millwood) (2016) 0.77
Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience (2016) 0.77
Long-term survival analysis of korean breast cancer patients at a single center: improving outcome over time. Yonsei Med J (2014) 0.77
Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. Cancer Causes Control (2014) 0.77
The geographic distribution of mammography resources in Mississippi. Online J Public Health Inform (2014) 0.77
Breast cancer molecular subtypes of Uygur and Han in Xinjiang of China. Int J Clin Exp Med (2014) 0.77
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist (2016) 0.77
Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma. Anticancer Res (2011) 0.76
Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study. Cancer Causes Control (2015) 0.76
Association of genetic ancestry with breast cancer in ethnically diverse women from Chicago. PLoS One (2014) 0.76
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat (2014) 0.76
Outcome Disparities in African American Compared with European American Women with ER+HER2- Tumors Treated within an Equal-Access Health Care System. Ethn Dis (2016) 0.76
The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells. Oncotarget (2015) 0.76
Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. Genetics (2016) 0.75
Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes. Breast Cancer Res (2017) 0.75
Size surprise? Tumour size, nodal status, and outcome after breast cancer. Curr Oncol (2012) 0.75
Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. Oncol Lett (2017) 0.75
Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. Endocr Relat Cancer (2016) 0.75
Toward a better understanding of race and cancer. Clin Cancer Res (2010) 0.75
184AA3: a xenograft model of ER(+) breast adenocarcinoma. Breast Cancer Res Treat (2015) 0.75
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat (2017) 0.75
Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Res Treat (2016) 0.75
How interacting pathways are regulated by miRNAs in breast cancer subtypes. BMC Bioinformatics (2016) 0.75
Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis? Indian J Surg Oncol (2016) 0.75
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat (2016) 0.75
Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. Sci Rep (2016) 0.75
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.75
Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features. Sci Rep (2016) 0.75
Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study. Breast Cancer Res (2017) 0.75
Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study. PLoS One (2015) 0.75
TraceRNA: a web application for competing endogenous RNA exploration. Circ Cardiovasc Genet (2014) 0.75
Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). J Breast Health (2013) (2014) 0.75
Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies. Cancer Prev Res (Phila) (2016) 0.75
Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. Cancer (2016) 0.75
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist (2015) 0.75
The characterization of cell line crl-2335 as a Basal-like breast carcinoma model. Breast Cancer (Auckl) (2011) 0.75
Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS One (2016) 0.75
Incidence of cancers in patients with atherosclerotic cardiovascular diseases. Int J Cardiol Heart Vasc (2017) 0.75
Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat (2017) 0.75
Racial differences in adjuvant endocrine therapy use and discontinuation in association with mortality among Medicare breast cancer patients by receptor status. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines (2016) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Causal diagrams for epidemiologic research. Epidemiology (1999) 19.48
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol (1994) 6.47
The hazards of hazard ratios. Epidemiology (2010) 5.24
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (2008) 2.97
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol (2000) 2.93
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol (2006) 2.92
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat (1995) 2.31
Using the National Death Index to obtain underlying cause of death codes. J Occup Environ Med (1998) 1.90
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast (2007) 1.64
Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol (2008) 1.64
Assessing the impact of screening mammography: Breast cancer incidence and mortality rates in Connecticut (1943-2002). Breast Cancer Res Treat (2006) 1.53
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Identifying a national death index match. Am J Epidemiol (2009) 1.48
Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev (2009) 1.41
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat (2008) 1.33
Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst (2010) 1.33
Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer (2009) 1.24
Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev (2009) 1.20
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol (2007) 1.16
Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol (2009) 1.12
Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol (2009) 1.10
Frequency of the basal-like phenotype in African breast cancer. APMIS (2007) 1.09
Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer (2009) 1.05
Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med Oncol (2008) 0.92
Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg (2008) 0.90
Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol Rep (2008) 0.86
Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet (2008) 0.85
Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Res Treat (2010) 0.83
Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining. World J Surg (2008) 0.82
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
International network of cancer genome projects. Nature (2010) 20.35
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (2009) 9.00
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat (2008) 5.52
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Familial adenomatous polyposis. Am J Gastroenterol (2006) 3.77
Use of multiple imputation in the epidemiologic literature. Am J Epidemiol (2008) 3.76
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science (2013) 3.52
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2005) 3.26
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet (2006) 3.19
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
The landscape of recombination in African Americans. Nature (2011) 3.06
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74